| Literature DB >> 33195692 |
Amin Sadeghi1, Mehrdad Halaji1, Amirhossein Fayyazi1, Seyed Asghar Havaei1.
Abstract
INTRODUCTION: Urinary tract infection (UTI) is one of the most frequent infections in kidney transplant patients (KTPs). This infection is mainly caused by uropathogenic Escherichia coli (UPEC). Plasmid-mediated quinolone resistance (PMQR) was also increasingly identified in UPEC. This study proposed to investigate the frequency of quinolone-resistance plasmid genes and the O-antigen serogroup among UPEC isolated from KTPs and non-KTP with UTI.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33195692 PMCID: PMC7641683 DOI: 10.1155/2020/2850183
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Antimicrobial susceptibility pattern of UPEC isolates among KTP and control group.
| Antibiotic | Total | KTP (49) | Control group (65) |
|
|---|---|---|---|---|
| Nalidixic acid | 79 | 37(75.5) | 42 (64.6) | 0.21 |
| Ciprofloxacin | 52 | 27 (55.1) | 25 (38.5) | 0.07 |
| Ofloxacin | 57 | 25 (51) | 32 (49.2) | 0.85 |
| Norfloxacin | 50 | 27 (55.1) | 23 (35.4) |
|
Distribution of qnr genes and O-serogroups among KTP and control group.
| Genes | Total | KTP (49) | Control group (65) |
|
|---|---|---|---|---|
|
| 18 (15.8) | 6 (12.2) | 12 (18.5) | 0.36 |
|
| 38 (33.3) | 15 (30.6) | 23 (35.4) | 0.59 |
|
| 4 (3.5) | 4 (8.2) | 0 (0) |
|
|
| 3 (2.6) | 0 (0) | 3 (4.6) | 0.12 |
|
| 4 (3.5) | 0 (0) | 4 (6.2) | 0.07 |
|
| 4 (3.5) | 0 (0) | 4 (6.2) | 0.07 |
|
| 23 (20.2) | 14 (28.6) | 9 (13.8) |
|
Distribution of qnr genes among quinolone resistance in KTP.
| Antibiotic | Pattern |
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Nalidixic acid | R ( | 10 (27) | 27 (73) | 0.47 | 4 (10.8) | 33 (89.2) | 0.59 |
| S ( | 5 (41.7) | 7 (58.3) | 2 (16.7) | 10 (83.3) | |||
| Ciprofloxacin | R ( | 9 (33.3) | 18 (66.7) | 0.64 | 3 (11.1) | 24 (88.9) | 0.78 |
| S ( | 6 (27.3) | 16 (72.7) | 3 (13.6) | 19 (86.4) | |||
| Ofloxacin | R ( | 9 (36) | 16 (64) | 0.40 | 2 (8) | 23 (92) | 0.35 |
| S ( | 6 (25) | 18 (75) | 4 (16.7) | 20 (83.3) | |||
| Norfloxacin | R ( | 9 (33.3) | 18 (66.7) | 0.64 | 3 (11.1) | 24 (88.9) | 0.78 |
| S ( | 6 (27.3) | 16 (72.7) | 3 (13.6) | 19 (86.4) |
Abbreviations: R: resistant; S: susceptible.
Distribution of qnr genes about quinolone resistance in control-group.
| Antibiotic | Pattern |
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Nalidixic acid | R ( | 12 (28.6) | 30 (71.4) | 0.12 | 9 (21.4) | 33 (78.6) | 0.51 |
| S ( | 11 (47.8) | 12 (52.2) | 3 (13) | 20 (87) | |||
| Ciprofloxacin | R ( | 8 (32) | 17 (68) | 0.65 | 6 (24) | 19 (76) | 0.51 |
| S ( | 15 (37.5) | 25 (62.5) | 6 (15) | 34 (85) | |||
| Ofloxacin | R ( | 11 (34.4) | 21 (65.6) | 0.86 | 7 (21.9) | 25 (78.1) | 0.48 |
| S ( | 12 (36.4) | 21 (63.6) | 5 (15.2) | 28 (84.8) | |||
| Norfloxacin | R ( | 7 (30.4) | 16 (69.6) | 0.53 | 6 (26.1) | 17 (73.9) | 0.31 |
| S ( | 16 (38.1) | 26 (61.9) | 6 (14.3) | 36 (85.7) |
Abbreviations: R: resistant; S: susceptible.
Antimicrobial resistance pattern in UPEC isolates based on serogroups in KTP.
| Antibiotic | Pattern |
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Nalidixic acid | R( | 4 (10.8) | 33 (89.2) | 0.23 | 9 (24.3) | 28 (75.7) | 0.28 |
| S ( | 0 (0) | 12 (100) | 5 (41.7) | 7 (58.3) | |||
| Ciprofloxacin | R ( | 3 (11.1) | 24 (88.9) | 0.40 | 7 (25.9) | 20 (74.1) | 0.65 |
| S ( | 1 (4.5) | 21 (95.5) | 7 (31.8) | 15 (68.2) | |||
| Ofloxacin | R ( | 2 (8) | 23 (92) | 0.96 | 7 (28) | 18 (72) | 0.92 |
| S ( | 2 (8.3) | 22 (91.7) | 7 (29.2) | 17 (70.8) | |||
| Norfloxacin | R ( | 3 (11.1) | 24 (88.9) | 0.40 | 7 (25.9) | 20 (74.1) | 0.65 |
| S ( | 1 (4.5) | 21 (95.5) | 7 (31.8) | 15 (68.2) |
Abbreviations: R: resistant; S: susceptible.
Antimicrobial resistance pattern in UPEC isolates based on serogroups in the control group.
| Antibiotic | Pattern |
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nalidixic acid | R( | 2 (4.8) | 40 (95.2) | 0.93 | 2 (4.8) | 40 (95.2) | 0.52 | 3 (7.1) | 39 (92.9) | 0.65 | 7 (16.7) | 35 (83.3) | 0.47 |
| S ( | 1 (4.3) | 22 (95.7) | 2 (8.7) | 21 (91.3) | 1 (4.3) | 22 (95.7) | 2 (8.7) | 21 (91.3) | |||||
| Ciprofloxacin | R ( | 1 (4) | 24 (96) | 0.85 | 1 (4) | 24 (96) | 0.56 | 2 (8) | 23 (92) | 0.62 | 7 (28) | 18 (72) |
|
| S ( | 2 (5) | 38 (95) | 3 (7.5) | 37 (92.5) | 2 (5) | 38 (95) | 2 (5) | 38 (95) | |||||
| Ofloxacin | R ( | 1 (3.1) | 31 (96.9) | 0.57 | 1 (3.1) | 31 (96.9) | 0.31 | 2 (6.3) | 30 (93.7) | 0.97 | 7 (21.9) | 25 (78.1) | 0.06 |
| S ( | 2 (6.1) | 31 (93.9) | 3 (9.1) | 30 (90.9) | 2 (6.1) | 31 (93.9) | 2 (6.1) | 31 (93.9) | |||||
| Norfloxacin | R ( | 0 (0) | 23 (100) | 0.18 | 1 (4.3) | 22 (95.7) | 0.65 | 2 (8.7) | 21 (91.3) | 0.52 | 7 (30.4) | 16 (69.6) |
|
| S ( | 3 (7.1) | 39 (92.9) | 3 (7.1) | 39 (92.9) | 2 (4.8) | 40 (95.2 | 2 (4.8) | 40 (95.2) |
Abbreviations: R: resistant; S: susceptible.